Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors.

Seema Gupta, Abdullah Farooque, J. S. Adhikari, Saurabh Singh, B. S. Dwarakanath

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The development of an approach based on the energy-linked modification of DNA repair and cellular recovery processes using 2-deoxy-D-glucose (2-DG; inhibitor of glycolytic ATP production) has shown promising results in a number of model systems of cancer. Following encouraging results on the tolerance and toxicity (acute as well as late effects) of the combination (2-DG and hypofractionated radiotherapy) in Phase I and II clinical trials, its efficacy is currently under evaluation in Phase III clinical trials for glioma patients. Since heterogeneous physiologic and metabolic status in tumors as well as host-tumor interactions influence the local tumor control, which coupled with systemic disturbances could determine the cure (long-term tumor free survival), investigations on the in vivo responses of tumors to the combined treatment have received considerable attention. This communication provides a brief overview on the in vivo studies related to radio- and chemosensitization of tumors by 2-DG, besides the normal tissue toxicity induced by the combined treatment of 2-DG and radiation or chemotherapeutic drugs.

Original languageEnglish (US)
JournalJournal of Cancer Research and Therapeutics
Volume5 Suppl 1
StatePublished - Sep 2009
Externally publishedYes

Fingerprint

Deoxyglucose
Radiation
Pharmaceutical Preparations
Neoplasms
Phase III Clinical Trials
Phase II Clinical Trials
Clinical Trials, Phase I
Radio
Glioma
DNA Repair
Radiotherapy
Adenosine Triphosphate
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Gupta, S., Farooque, A., Adhikari, J. S., Singh, S., & Dwarakanath, B. S. (2009). Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors. Journal of Cancer Research and Therapeutics, 5 Suppl 1.

Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors. / Gupta, Seema; Farooque, Abdullah; Adhikari, J. S.; Singh, Saurabh; Dwarakanath, B. S.

In: Journal of Cancer Research and Therapeutics, Vol. 5 Suppl 1, 09.2009.

Research output: Contribution to journalArticle

Gupta, Seema ; Farooque, Abdullah ; Adhikari, J. S. ; Singh, Saurabh ; Dwarakanath, B. S. / Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors. In: Journal of Cancer Research and Therapeutics. 2009 ; Vol. 5 Suppl 1.
@article{68899fc821bd4f6da43151356b05eeef,
title = "Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors.",
abstract = "The development of an approach based on the energy-linked modification of DNA repair and cellular recovery processes using 2-deoxy-D-glucose (2-DG; inhibitor of glycolytic ATP production) has shown promising results in a number of model systems of cancer. Following encouraging results on the tolerance and toxicity (acute as well as late effects) of the combination (2-DG and hypofractionated radiotherapy) in Phase I and II clinical trials, its efficacy is currently under evaluation in Phase III clinical trials for glioma patients. Since heterogeneous physiologic and metabolic status in tumors as well as host-tumor interactions influence the local tumor control, which coupled with systemic disturbances could determine the cure (long-term tumor free survival), investigations on the in vivo responses of tumors to the combined treatment have received considerable attention. This communication provides a brief overview on the in vivo studies related to radio- and chemosensitization of tumors by 2-DG, besides the normal tissue toxicity induced by the combined treatment of 2-DG and radiation or chemotherapeutic drugs.",
author = "Seema Gupta and Abdullah Farooque and Adhikari, {J. S.} and Saurabh Singh and Dwarakanath, {B. S.}",
year = "2009",
month = "9",
language = "English (US)",
volume = "5 Suppl 1",
journal = "Journal of Cancer Research and Therapeutics",
issn = "0973-1482",
publisher = "Medknow Publications and Media Pvt. Ltd",

}

TY - JOUR

T1 - Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors.

AU - Gupta, Seema

AU - Farooque, Abdullah

AU - Adhikari, J. S.

AU - Singh, Saurabh

AU - Dwarakanath, B. S.

PY - 2009/9

Y1 - 2009/9

N2 - The development of an approach based on the energy-linked modification of DNA repair and cellular recovery processes using 2-deoxy-D-glucose (2-DG; inhibitor of glycolytic ATP production) has shown promising results in a number of model systems of cancer. Following encouraging results on the tolerance and toxicity (acute as well as late effects) of the combination (2-DG and hypofractionated radiotherapy) in Phase I and II clinical trials, its efficacy is currently under evaluation in Phase III clinical trials for glioma patients. Since heterogeneous physiologic and metabolic status in tumors as well as host-tumor interactions influence the local tumor control, which coupled with systemic disturbances could determine the cure (long-term tumor free survival), investigations on the in vivo responses of tumors to the combined treatment have received considerable attention. This communication provides a brief overview on the in vivo studies related to radio- and chemosensitization of tumors by 2-DG, besides the normal tissue toxicity induced by the combined treatment of 2-DG and radiation or chemotherapeutic drugs.

AB - The development of an approach based on the energy-linked modification of DNA repair and cellular recovery processes using 2-deoxy-D-glucose (2-DG; inhibitor of glycolytic ATP production) has shown promising results in a number of model systems of cancer. Following encouraging results on the tolerance and toxicity (acute as well as late effects) of the combination (2-DG and hypofractionated radiotherapy) in Phase I and II clinical trials, its efficacy is currently under evaluation in Phase III clinical trials for glioma patients. Since heterogeneous physiologic and metabolic status in tumors as well as host-tumor interactions influence the local tumor control, which coupled with systemic disturbances could determine the cure (long-term tumor free survival), investigations on the in vivo responses of tumors to the combined treatment have received considerable attention. This communication provides a brief overview on the in vivo studies related to radio- and chemosensitization of tumors by 2-DG, besides the normal tissue toxicity induced by the combined treatment of 2-DG and radiation or chemotherapeutic drugs.

UR - http://www.scopus.com/inward/record.url?scp=77951227475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951227475&partnerID=8YFLogxK

M3 - Article

C2 - 20009287

AN - SCOPUS:77951227475

VL - 5 Suppl 1

JO - Journal of Cancer Research and Therapeutics

JF - Journal of Cancer Research and Therapeutics

SN - 0973-1482

ER -